Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This study is examining the safety and efficacy of converting anti-rejection therapy from
mycophenolic acid (MPA) to Zortress (everolimus) in renal transplant recipients with BK virus
infection.
The study will also determine if immune monitoring tests can detect an association between BK
virus infection and transplant rejection episodes, based on the specific BKV infection
treatment regimen.
The investigators hypothesize that an anti-rejection regimen with Zortress (everolimus) and
tacrolimus + prednisone will be superior to a standard regimen of reduced dose MPA and
tacrolimus + prednisone in patients who have undergone renal transplantation and have active
BKV infections.